Form 4: Absci Director Receives Equity Compensation Grant

Director Menelas N. Pangalos was granted 10,100 restricted stock units and 39,800 stock options as part of annual compensation.

Summary

• Director Menelas N. Pangalos acquired 10,100 Restricted Stock Units (RSUs) on June 4, 2026.
• The director was also granted 39,800 stock options with an exercise price of $7.34 per share.
• Both the RSUs and stock options vest on the earlier of the first anniversary of the grant or the date of the next annual stockholders meeting.
• Following these transactions, the director's direct beneficial ownership of common stock increased to 242,408 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standardized vesting schedule tied to continued service.

Negatives

• Issuance of equity results in minor dilution to existing shareholders.

Risks

• Future share price volatility may impact the value of the granted options.
• Vesting is contingent upon the director's continuous service to the company.

Future Outlook

The equity grants are subject to vesting conditions based on the director's continued service through the next annual meeting or the first anniversary of the grant.

Management Comments

• The transactions were executed under the Absci Corporation 2021 Stock Option and Incentive Plan.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure long-term alignment with company performance.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is consistent with standard practices for mid-cap biotech firms.
• Vesting periods of one year or until the next annual meeting are typical for board-level equity awards.

Corporate Governance

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of RSUs and options on the earlier of June 4, 2027, or the next annual meeting.

Key Dates

Keywords

Absci, ABSI, Form 4, Insider Trading, Equity Compensation, Director Compensation